NexgenRx Reports Impressive Year-End Results with Positive Revenue Growth

Monday, 8 April 2024, 18:00
NexgenRx recently disclosed its 2023 year-end results, exhibiting robust revenue increments and sustained positive EBITDA. The fourth quarter also saw the company reporting a GAAP EPS of -C$0.005. Overall, NexgenRx's performance indicates a trend of stable financial growth amidst market fluctuations.
LivaRava Finance Meta Image
NexgenRx Reports Impressive Year-End Results with Positive Revenue Growth

NexgenRx Reports Q4 Results

NexgenRx announces 2023 year-end results, showing solid revenue growth and continued positive EBITDA. Q4 GAAP EPS of -C$0.005.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe